首页 | 本学科首页   官方微博 | 高级检索  
     

超未成熟儿视网膜病变术后屈光状态分析
引用本文:王建勋,项道满,胡兰香,陈锋,龙静姬,宋生芳. 超未成熟儿视网膜病变术后屈光状态分析[J]. 眼科新进展, 2015, 0(7): 649-651. DOI: 10.13389/j.cnki.rao.2015.0177
作者姓名:王建勋  项道满  胡兰香  陈锋  龙静姬  宋生芳
作者单位:510623 广东省广州市,广州市妇女儿童医疗中心眼科
摘    要:目的 研究出生体质量<1000g的早产儿视网膜病变患儿经过抗血管内皮生长因子玻璃体内注射后矫正胎龄6个月大时的眼位、注视功能及屈光状态情况。方法 横断面研究,回顾性队列研究。出生体质量<1000g、因早产儿视网膜病变接受抗血管内皮生长因子玻璃体内注射的32例(64眼)患儿,于矫正胎龄6个月大时检查其注视功能、眼位,并散瞳验光。按治疗前眼底有无纤维增殖进行分组,观察两组屈光性弱视发生风险有无统计学差异。结果 矫正胎龄6个月大时,32例64眼中近视眼者29眼(45.3%),近视度数为-0.75~-4.00(-2.03±0.71)DS;远视眼32眼(50.0%),远视度数为+1.00~+4.00(+1.78±0.76)DS;存在或合并散光者28眼(43.8%),散光度数为1.00~6.00(2.39±1.13)DC。所有患儿均为正位眼且中心注视,无注视抑制;治疗前眼底纤维增殖组中,有屈光性弱视风险的比例为75.0%(12/16);无纤维增殖组中,有屈光性弱视风险的比例为25.0%(4/16),两者相比差异具有统计学意义(P=0.032)。结论 出生体质量<1000g早产儿接受抗血管内皮生长因子玻璃体内注射术后矫正胎龄6个月大时,表现出中心注视及正位眼,无注视抑制。治疗前眼底纤维增殖组发生屈光性弱视的风险大于无纤维增殖组。

关 键 词:早产儿视网膜病变  屈光不正  超未成熟儿  婴幼儿  抗血管内皮生长因子药物

 Refractive outcome of retinopathy of prematurity in extremely low birth weight infants after intravitreal injection of bevacizumab
WANG Jian-Xun,XIANG Dao-Man,HU Lan-Xiang,CHEN Feng,LONG Jing-Ji,SONG Sheng-Fang.  Refractive outcome of retinopathy of prematurity in extremely low birth weight infants after intravitreal injection of bevacizumab[J]. Recent Advances in Ophthalmology, 2015, 0(7): 649-651. DOI: 10.13389/j.cnki.rao.2015.0177
Authors:WANG Jian-Xun  XIANG Dao-Man  HU Lan-Xiang  CHEN Feng  LONG Jing-Ji  SONG Sheng-Fang
Affiliation:Department of Ophthatmology, Guangzhou Women and Children Medical Center, Guangzhou 510623 , Guangdong Province , China
Abstract:Objective To observe ocular position , fixation ability , and refractive error of retinopathy of prematurity ( ROP) in infants with birth mass < 1000 g at 6 months ( corrected age) , who had received intravitreal injection of bevacizumab. Methods This is a cross-sectional and retrospective cohort study from a single center. Thirty-two extremely low birth weight infants with ROP got intravitreal injection of bevacizumab. At 6 months ( corrected age) , ocular position, fixation ability were measured. Meanwhile refractive data from retinoscopy under ciliary muscles paralyzed were recorded. These infants were classified int0 2 groups by the fact that the extraretinal fibrovascular proliferation was occurred or not before surgery. Results In 64 eyes of 32 infants,29 eyes (45. 3% ) were myopia,the myopic degree was from - 0. 75 DS to -4. 00 DS , mean ( - 2. 03 +0. 71 ) DS ; 32 eyes ( 50. 0% ) were hyperopia , the hyperopic degree was from + 1. 00 DS to +4. 00 DS.mean ( + 1. 78 +0. 76) DS ;28 eyes (43. 8% ) presented astigmatism , the astigmatism degree was from l. 00 DC t0 6. 00 DC , mean ( 2. 39 + 1. 13 ) DC. All patients showed orthophoria and central steady maintain fixation. There was no fixation suppression. The incidence of amblyopia due to severe refractive error in infants with extraretinal fibrovascular proliferation ( 75. 0% . 12/16) was higher than that in infants without extraretinal fibrovascular proliferation ( 25. 0% . 4/16 ) . Conclusion Infants with birth mass < 1000 g with ROP can develop orthophoria and quality fixation at 6 months ( corrected age) and there is no fixation suppression in these infants. Extraretinal fibrovascular proliferation before surgery may be a risk for severe refractive error.
Keywords:retinopathy of prematurity  refractive errors  extremely low birth weight  infants  anti-vascular endothelial growth factor drug
点击此处可从《眼科新进展》浏览原始摘要信息
点击此处可从《眼科新进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号